Royce & Associates LP boosted its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 88.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 526,985 shares of the company's stock after acquiring an additional 248,081 shares during the quarter. Royce & Associates LP owned 0.31% of Envista worth $10,166,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its holdings in shares of Envista by 22.2% during the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock valued at $69,749,000 after purchasing an additional 642,401 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the 4th quarter valued at about $53,000. Lecap Asset Management Ltd. bought a new stake in shares of Envista during the 4th quarter worth about $281,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Envista in the 3rd quarter worth approximately $14,965,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Envista by 2.5% in the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock valued at $57,233,000 after acquiring an additional 71,435 shares in the last quarter.
Analyst Ratings Changes
Several brokerages recently commented on NVST. Piper Sandler boosted their target price on Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Wells Fargo & Company set a $19.00 price objective on Envista in a research note on Saturday, March 8th. JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Jefferies Financial Group upped their price target on shares of Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Finally, New Street Research set a $19.00 price objective on shares of Envista in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $20.18.
Check Out Our Latest Research Report on Envista
Envista Trading Down 1.5 %
Envista stock traded down $0.26 during midday trading on Friday, reaching $16.63. The stock had a trading volume of 12,252,515 shares, compared to its average volume of 2,323,134. The firm's fifty day simple moving average is $19.80 and its two-hundred day simple moving average is $19.59. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -2.56, a PEG ratio of 1.27 and a beta of 1.33.
Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities analysts anticipate that Envista Holdings Co. will post 1 EPS for the current fiscal year.
Envista Company Profile
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Read More
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
